Activity-Dependent Gene Therapy for Refractory Epilepsy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapies for refractory epilepsy lack specificity and are associated with off-target effects, as they permanently modify neuronal excitability or require additional steps for on-demand modulation, and existing treatments are limited by risks of damage to adjacent brain structures.
Innovation Solution
The use of neuronal activity-dependent promoters, such as c-Fos, to selectively modulate genes like KCNA1 or dCas9, which are only expressed during intense neuronal activity, reducing excitability only in over-active neurons and returning to baseline when activity normalizes, thereby minimizing off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If permanent gene modification is used to treat refractory epilepsy, then therapeutic effect is improved, but off-target effects and side effects increase
Solution Approach 1:
The patent employs a dynamic gene expression system controlled by an activity-dependent promoter (c-Fos) that responds to neuronal activity levels. The promoter activates only during intense neuronal firing associated with seizures, driving transient expression of therapeutic genes (KCNA1, GAD67, NPY) precisely when needed, rather than permanent constitutive expression. This dynamic control ensures therapeutic effect during seizure events while avoiding continuous off-target effects on normal neuronal function.
Solution Approach 2:
The patent changes the expression parameter of therapeutic genes from static/permanent to dynamic/activity-dependent. By coupling gene expression to the c-Fos promoter, the system responds to physiological parameter changes (neuronal activity levels) and adjusts gene expression accordingly. This parameter change allows the therapy to be activated only during pathological states (seizures) while remaining inactive during normal physiological conditions, thereby reducing off-target effects.
2Reliability
If surgical resection of epileptogenic zone is performed, then seizure freedom is achieved, but risk of damage to eloquent regions increases
Solution Approach 1:
The patent applies local quality by targeting gene expression specifically to hyperactive neurons within the epileptogenic zone through activity-dependent promoter activation. The c-Fos promoter ensures that therapeutic genes are expressed only in neurons experiencing intense firing during seizures, rather than uniformly across all neurons in the resection area. This localized and selective approach treats the pathological focus while preserving surrounding eloquent brain structures and their functions.
Solution Approach 2:
The patent employs a self-service mechanism where the pathological neuronal activity itself (seizure-related intense firing) activates the c-Fos promoter, which in turn drives expression of therapeutic genes that suppress the abnormal activity. The system uses the disease process (hyperactivity) as its own trigger, automatically activating therapy only when and where seizures occur, without requiring external surgical intervention or damage to eloquent regions.
3Measurement precision
If optogenetics or chemogenetics is used for on-demand modulation, then cell-type specificity is improved, but device complexity and additional intervention steps increase
Solution Approach 1:
The patent extracts the external control mechanism (light delivery for optogenetics or drug administration for chemogenetics) and replaces it with an endogenous activity-dependent promoter system. The c-Fos promoter inherently responds to neuronal activity without requiring external optogenetic stimulation or chemogenetic drug delivery. This extraction eliminates the need for complex external devices and intervention steps while maintaining cell-type specificity through promoter activation in hyperactive neurons.
Solution Approach 2:
The patent introduces the c-Fos promoter as an intermediary between neuronal activity and therapeutic gene expression. Instead of directly using optogenetic or chemogenetic approaches that require external mediators (light or drugs), the system uses the naturally occurring c-Fos promoter as an endogenous mediator that translates neuronal activity levels into selective gene expression. This intermediary simplifies the system by eliminating external control mechanisms while preserving activity-dependent specificity.
Data Source
AI summary
The invention provides expression vectors or vector systems comprising a polynucleotide sequence encoding a polypeptide, wherein the gene is operably linked to a neuronal activity-dependent promoter suitable to drive expression of the gene product in a subject’s neural cells. The features of the expression vectors combine to advantageously improve the treatment of a neurological disorder associated with neuronal hyperexcitability in a subject. The invention also provides the expression vectors or vector systems for use in related methods of treatment, as well as viral particles, cells, kits and methods using the expression vectors or vector systems.